

CURRICULUM VITAE

Yaquelin Rodriguez, CRC, FMG

Date of Birth: November 22, 1966

Place of Birth: Cuba

Languages: English and Spanish (Fluent)

Home Address: 201 NW 27 Court
Miami, Florida 33125

Office Address: Clinical Pharmacology of Miami, Inc.
550 West 84 Street
Miami, Fl. 33014

Office Telephone: 305-817-2900
305-817-8234 (fax)
305-746-9352 (cell)

E-Mail Address: yrodriguez@clinpharmmiami.com

EDUCATION

Instituto Superior de Ciencias Medicas Havana
Havana, Cuba
1984-1990 (Medical Doctor)

Family Practice Specialty
Jose Cardenas Hospital
Matanzas, Cuba
1990-1994

Medical Terminology Course
Sarasota County Vocational School
Sarasota, FL
1999

Cosmetic Procedure Training
Sarasota, FL
2000

Certifications: ARMA GCP, ACLS/BLS, OSHA Compliance, Oral Dosing Procedures, HIV/Aids Education
Computer Proficiency: Microsoft Word, MS Excel, MS Outlook, WordPerfect and Corel Word Perfect

Current Position: Clinical Research Coordinator
Clinical Pharmacology of Miami, Inc.
550 West 84 Street
Miami, Fl. 33014
2008 - Present

Prior Work Experience: Clinical Research Coordinator
Elite Research Institute
15705 NW 13th Ave
Miami, Florida 33169
2007 – 2008

Project Manager
SFBC International, Inc.
11190 Biscayne Blvd
Miami, Florida 33181
2003 – 2006

Clinical Research Coordinator
Clinical Pharmacology Associates
2060 N.W. 22nd Avenue
Miami, Florida 33142
2001 – 2003

Medical Assistant
Sarasota/Florida-ADF Dermatology Office
Sarasota, FL
1999-2001

Medical Doctor
Betancourt Neningen Clinic Cuba
Havana, Cuba
1996–1998

Medical Doctor
Cardenas/Matanzas/Cuba
Matanzas, Cuba
1990–1996

Research Experience:

“A phase 1, Single dose, Open label trial of Fumaryl Diketopiperazine administered as Technosphere Inhalation powder in Diabetes Subjects with Mild or moderate Nephropathy versus matched Diabetic subjects with normal renal function”—02-2008

“The relative Bioavailability of two NOVEN Vivelle-Mini Estradiol Transdermal System ETS (to Vivelle” EST.02-08

‘An open Label, Pharmacokinetic study of a Pulsatil GnRH Iontophoretic Patch compared to Pulsatile GnRH delivered via subcutaneous pump in healthy Pre-menopausal Female subjects.12-20

“A Multicenter, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of MEM 1003 in patients with mild to moderate Alzheimer’s Disease.(2007)

“An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of study drug in Subjects with Mild to Moderate Hepatic Impairment with that in Matched Healthy Control Subjects.”

“An Open, Randomized, 2-Period, Crossover, Pilot Study to Investigate the Influence of Vitamin D3 on the Oral Administration of Alendronate”

“An Open, Randomized. 3-Period, Crossover study in postmenopausal females to determine the oral Bioavailability of the 35 and 70-mg Alendronate tablets.”

“A Double-Blind, Placebo-Controlled, Double-dummy, parallel-group Study to Evaluate and Compare the Effects of 15 Days of Treatment with Oral Rofecoxib, Oral Naproxen, Oral Celecoxib or Placebo on Urinary Sodium Excretion and Other Renal Functions in Subjects 60 to 80 years of age consuming a 200 mEq Sodium Diet”.

“An Open-Label, Randomized, 2-Period, Crossover Study to Examine the Influence of Timing of Meal Ingestion on the Relative Bioavailability of Study drug in Healthy Subjects”

“An Open, Randomized, Single Dose, Four Period Crossover Study to Demonstrate the Bioequivalence of Simvastatin Tables and Encapsulated Simvastatin Tablets in Healthy Male and Female Subjects”

“An Open Label Study to Evaluate The Effect of Concomitant Chronic Administration of Topiramate or Ethinyl Carbamazepina on the Pharmacokinetics of Norethindrone and Estradiol (Ortho-Novum 1/35) in Healthy Non-Obese and Healthy Obese Female Subjects”

“Effects of cimetidine and probenecid on study drug renal clearance in healthy young human subjects”

Research Experience (cont..)

“An Open, Randomized, 2-Period, Crossover, Pilot Study to Investigate the Influence of Vitamin D3 on the Oral Absorption of Alendronate”

“A Double-Blind, Randomized, Placebo-Controlled, Escalating Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of study drug in Healthy Elderly Females, and Healthy Young Female Volunteers”

“A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel-Group Study to Evaluate and Compare the Effects of 15 Days of Treatment with Oral Etoricoxib, Oral Celecoxib, Oral Naproxen, or Placebo on Urinary Sodium Excretion, Blood Pressure, and Other Renal Functions in Subjects 60-85 Years of Age Consuming a 200-mEq Sodium diet”

“A Double-Blind Ascending Oral Dose Evaluation of Study Drug for Safety, Tolerance, and Preliminary Pharmacokinetic Profile in Healthy Subjects”

“A 2-Part, Open-Label, Randomized, Multiple, Oral-Dose, Study Comprised of 2-Crossover Periods per Part, to Investigate the Pharmacokinetic Interaction Between Simvastatin and Fenofibrate In Young Healthy Male and Female Subjects”

“A Randomized, Double-Blind, Placebo-controlled, Ascending, Oral Dose Evaluation of Study Drug for Safety, Tolerance, and a Preliminary Pharmacokinetic Profile in Healthy Subjects: Multiple Dose Administration”

“An Open-Label, Randomized, Single-Dose, Four Period Crossover Study to Evaluate the Bioequivalence of Simvastatin Tablets and Encapsulated Simvastatin Tablets in Healthy Male and Female Subjects”

“A Randomized, Partially Blinded, Placebo-Controlled, 3-Period Study in Healthy Subjects to Evaluate the Effects of Diltiazem and Food on the Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of Study drug”

“An Open-label Study to Investigate the Absorption, Metabolism, Excretion and Mass Balance After Oral Administration of a Single Dose of [14C]-Study Drug in Healthy Adult Male Subjects”

“A Study to Evaluate the Multiple Dose Pharmacokinetics of a Hydrocodone/Naltrexone/Acetaminophen (HXA) Combination Tablet in Healthy Subjects”

“An Open-Label Crossover Study to Evaluate the Bioequivalence of Coated Hydrocodone/Naltrexone /Acetaminophen (HXA), High and low dose Uncoated Hydrocodone/Naltrexone (HX), and Uncoated Hydrocodone (H) Tablets in Healthy Subjects”

Research Experience (cont..)

“A Randomized, Single-Blinded, Placebo-Controlled, 2-Period, Crossover Study to Determine the Relative Bioavailability of study drug Suspension and Tablet Formulations in Healthy Male Subjects”

“An Open-Label, Randomized, 2-Period Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects.”

“A Phase 2, Randomized, Single-Blind, Placebo-Controlled Crossover Study to Examine the Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Study Drug Subcutaneous Injection in Healthy Subjects”

“A Placebo- and Positive- Controlled, Parallel Designed Study of the Electrocardiographic Effects of Intravenous Study Drug in Healthy Men and Women Volunteers”

“An Evaluation of the Steady-State and Single-Dose Pharmacokinetics of Medisorb Naltrexone in Healthy Subjects”

“An Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of Study Drug After Oral Administration of a Single Dose of ¹⁴C-Study Drug in Healthy Adult Male Subjects”

“A Randomized, Double-Blind, Placebo-Controlled, Drug Interaction Study of Multiple Oral Doses of Study Drug with Midazolam, a Cytochrome P450 Isoenzyme 3A4 Substrate, in Healthy Volunteers”

“Double Blind Randomized, Placebo-Controlled, Single dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Study Drug Tablets in Healthy Elderly Male and Female Subjects”.

“A Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Biochemical Activity, and Pharmacokinetics of Multiple Oral Doses of Study Drug in Overweight Postmenopausal Females”

"Phase I Dose Escalation Study to Examine the Safety, Tolerability, and Pharmacokinetics of Orally Administered Study Drug in Healthy Male Volunteers"

“A randomized, open-label, single-dose, four-way crossover study of the effects of varying doses of ethanol on the pharmacokinetic characteristics of 12-mg hydromorphone hydrochloride extended-release capsules (HHER) in two groups (fed and fasted) of healthy volunteers”

Research Experience (cont..)

“An Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of MK-0524 After Oral Administration of a Single Dose of [14C]- Study Drug in Healthy Adult Male Subjects”

“A Double-Blind Ascending Oral Dose Evaluation of Study Drug For Safety, Tolerance, and a Preliminary Pharmacokinetic Profile in Healthy Subjects”

“A Double-Blind, Randomized, Placebo-Controlled, 3-Part Study to Investigate the Safety and Tolerability of Study Drug Administered Twice-Daily or as Escalating, Once-Daily Titrated Doses in Healthy Obese Volunteers”

“A Phase I Study in Healthy Subjects to Evaluate the Effect of Steady-State Doses of Zelpar® (Zydis® Selegiline) on Blood Pressure Responses to Tyramine”

“A Phase I, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effect of 14-Day Treatment with Study Drug on the Single Pharmacokinetics (PK) of Atrovastatin, a Substrate for Cytochrome P450 3A4 (CYP3A4)”

“A 2-Period Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Study Drug in Healthy Volunteers”

“An open label, Pharmacokinetic Study of Pulsatile GnRH Iontophoretic Patch Compared to Pulsatile GnRH delivered via subcutaneous pump in healthy Premenopausal female subjects”. 2007

“A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and Lisinopril. 2007

“A phase I, age and gender ‘Stratified, open label, Parallel-Group, Single Dose Study Assessing the pharmacokinetics of a single 4.8g Oral Dose of SPd476 in Healthy male and female subjects. 2007

“A two- week, Randomized, double- Blind, repeat-Dose, parallel- group study to evaluate the safety and tolerability of Metformin 2000mg Co-administered with either GSK 189075 500mg BID or GSK 189075 750mg BID to subjects with Type 2 Diabetes Mellitus”.